Germany advanced a healthcare reform package despite drug discount pushback, with lawmakers voting to raise mandatory rebates on branded medicines and tighten certain insurance rules. The package was approved by the Bundestag and cleared the Bundesrat, setting the stage for cost-saving measures beginning next year. For pharma, the key impact is a lift in the fixed markdown drugmakers must pay on list prices for branded products—from 7% to 15.5%—while a variable rebate proposal was dropped after industry opposition earlier in summer. The reforms target multi-year savings across statutory health insurance, increasing pricing pressure in one of Europe’s largest markets. For biotech firms with revenue exposures in Germany, this signals near-term pricing environment tightening—affecting launch strategy, portfolio planning, and commercial forecasting across the EU.